Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
about
Idiotype vaccination for Non-Hodgkin lymphomaIdiotype vaccination for Non-Hodgkin lymphomaWhy do B cell lymphoma fail to elicit clinically sufficient T cell immune responses?B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.Spinning molecular immunology into successful immunotherapy.Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.Vaccination therapy for cutaneous T-cell lymphoma.New approaches in the immunotherapy of haematological malignancies.Idiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphomaTowards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma.Therapeutic idiotype vaccines in B lymphoproliferative diseases.Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.Multiple costimulatory modalities enhance CTL avidity.Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity.Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma.Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulinsDendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivoTherapeutic lymphoma vaccines: importance of T-cell immunity.Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.Therapeutic vaccine for lymphoma.Anti-idiotype antibodies in cancer treatment.BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.Chitosan solution enhances the immunoadjuvant properties of GM-CSF.Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaCpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myelomaFuture of idiotypic vaccination for B-cell lymphoma.Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccinesMyeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.Idiotype vaccine strategies for treatment of follicular lymphoma.Idiotype vaccines for lymphoma therapy.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.
P2860
Q24186272-699DDC01-0BD7-4F0C-A310-A1E3B55AB36EQ24235281-80AAA8D1-16D5-4F95-AA76-C94552F43C2FQ33536297-6B9F220C-0E76-4C92-80AF-4EEFBE896C96Q33776141-5566509A-E91F-409D-8344-E9C9CF9AF90DQ34097414-B09BFF9B-3304-492D-A3E9-9A4A9D486166Q34534544-7A078A9A-4377-480E-9F5C-6FB576AFD191Q34632056-8B1F563D-AF78-4E61-8CF6-AE3F4DB455CFQ34734310-DCF48EA0-10F4-4BC0-9525-51BEF8E6BDE1Q35015875-1CCE11BF-0A80-4DB2-8AC9-F349884CFAE4Q35106657-C1F2E793-D0AA-42E5-8A68-497D1B4753DDQ35113388-E428DA9C-9CA2-4FAE-B934-D183E9FF0D8AQ35114545-2081C624-B667-4951-81D6-732BA9803779Q35144751-ADEDE6FE-DCE0-49D6-88A7-FC1BE3611E0DQ35740264-DD953AFD-6FF4-427C-B875-C9F8CA47251DQ35790890-62AE0296-ADDD-43DB-8D42-B058F8221AE7Q35809463-319AD7C3-40AF-4C97-842C-D997114DBB83Q35839905-94945331-EC68-4167-B413-A51CB165B6C4Q35901490-8668519A-3215-4B62-8A4C-C332248AEC18Q36099441-5035C213-6EAE-4349-9679-FD72ABEDB813Q36194606-CA52C9A7-B6C8-4A49-972B-54B77816B563Q36386109-0B72E4B3-ED5C-4330-A818-3C50CF92CC20Q36407174-62A5157D-4A92-42B6-908C-5D2239CD0FE8Q36530231-15173CFC-72AB-426B-A4FD-927F3823C1A3Q36569004-F185AE63-C267-4AD0-A917-2748AB386870Q36625526-405A9540-D82E-421A-B69F-72E06F687353Q36675461-C8F9CCCF-164F-43EA-9005-23F50E9B7355Q36746586-60B15647-3FF0-4F3F-8169-63E5021988FAQ36832098-898D339A-896D-465A-ACAA-70FD404DA103Q36837124-64A54A3F-1523-4365-ADEB-0ED415D2559AQ36868870-63B55891-218F-4431-B699-D459931587E0Q36955402-FFEBFDF7-C0B4-43F8-8044-9988EB4AAD31Q37142202-78307B0A-311C-458E-BE18-97554F9497A2Q37169042-0345C2D1-AB57-41D7-849B-FF0F7016F221Q37260574-6C0102EA-5F23-4C0A-ACBC-725866FEF3DCQ37354174-0ED504E9-35C7-4771-BEF6-972E768C6F04Q37401011-137B3874-D562-4C8E-AB90-73C6C4A31755Q37412334-8DF49DF6-F577-4513-ACA7-6E083C73DF02Q37822740-659AD9EB-0F74-4D75-B5A7-E492BF501125Q37892587-FB07E9A1-8C08-43FB-952F-F8CA74768B63Q38149916-28B4C9E8-219F-4B30-8E99-D21896567295
P2860
Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaccination with syngeneic, ly ...... a protective T-cell response.
@en
Vaccination with syngeneic, ly ...... a protective T-cell response.
@nl
type
label
Vaccination with syngeneic, ly ...... a protective T-cell response.
@en
Vaccination with syngeneic, ly ...... a protective T-cell response.
@nl
prefLabel
Vaccination with syngeneic, ly ...... a protective T-cell response.
@en
Vaccination with syngeneic, ly ...... a protective T-cell response.
@nl
P2093
P2860
P356
P1476
Vaccination with syngeneic, ly ...... a protective T-cell response.
@en
P2093
P2860
P304
10972-10977
P356
10.1073/PNAS.93.20.10972
P407
P577
1996-10-01T00:00:00Z